# Eplerenone

Drug · id `cardio:eplerenone` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Inspra

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: High blood pressure; Coronary and vascular disease; Heart failure  

## In plain language

Eplerenone, sold as Inspra, is an aldosterone antagonist, a medicine taken by mouth. The US label read, for Inspra tablets, lists two uses in adults: improving survival in stable people who have symptomatic heart failure with reduced ejection fraction (40% or less) after a heart attack, and the treatment of high blood pressure to lower it.

## Technical summary

RxNorm ingredient 298869; UNII 6995V82D0B. MeSH descriptor D000077545 is Eplerenone. Class: Aldosterone Antagonist (FDA established pharmacologic class, RxClass). The label read is the Viatris Specialty LLC label for Inspra tablets, application NDA021437, effective 2025-06-23 in openFDA. Generic eplerenone labels were not read. This page records label indications, the mechanism sentence and the class only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: Adults with heart failure with reduced ejection fraction after a heart attack, and adults with hypertension, as described in the US label of Inspra tablets

Recipient: Adult; Population: Stable adult patients with symptomatic heart failure with reduced ejection fraction (40% or less) after an acute myocardial infarction, and adults with hypertension, as the indications section of the label states.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Adults, as the label states; Follow-up: Not applicable (label statement)

### The US label of Inspra (eplerenone tablets, Viatris Specialty LLC, application NDA021437; the version dated 2025-06-23 in openFDA) describes eplerenone as an aldosterone antagonist. It lists improving survival of stable adult patients with symptomatic heart failure with reduced ejection fraction (40% or less) after an acute myocardial infarction, and the treatment of hypertension in adults, to lower blood pressure.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Adult; Population: Stable adult patients with symptomatic heart failure with reduced ejection fraction (40% or less) after an acute myocardial infarction, and adults with hypertension, as the indications section of the label states.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Adults, as the label states; Follow-up: Not applicable (label statement)
- Limitations: This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Contraindications, warnings (including raised potassium), interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-18
- Sources:
  1. Supports: openFDA drug label record for Inspra (eplerenone tablets), Viatris Specialty LLC label: indications, mechanism, class (Regulator, edition The openFDA drug label record for set id 1a52bedc-8e2c-4116-a296-a87770676b4a (manufacturer Viatris Specialty LLC, application NDA021437), returned on 2026-11-18. The label text is dated 2025-06-23 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%221a52bedc-8e2c-4116-a296-a87770676b4a%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE. Retrieved 2026-11-18T17:27:10Z. Source state: Current. Version fingerprint: 5faf76d843730007ed843afc66f467edf02eeccc748524c7f0b7abcfb7138e90.
     How it applies: Label passage quoted in the research quote table (LB-04).
  2. Supports: openFDA drug label record for Inspra (eplerenone tablets), Viatris Specialty LLC label: indications, mechanism, class (Regulator, edition The openFDA drug label record for set id 1a52bedc-8e2c-4116-a296-a87770676b4a (manufacturer Viatris Specialty LLC, application NDA021437), returned on 2026-11-18. The label text is dated 2025-06-23 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%221a52bedc-8e2c-4116-a296-a87770676b4a%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1.1 Heart Failure Post-Myocardial Infarction. Retrieved 2026-11-18T17:27:10Z. Source state: Current. Version fingerprint: 5faf76d843730007ed843afc66f467edf02eeccc748524c7f0b7abcfb7138e90.
     How it applies: Label passage quoted in the research quote table (LB-05, LB-06).
  3. Supports: openFDA drug label record for Inspra (eplerenone tablets), Viatris Specialty LLC label: indications, mechanism, class (Regulator, edition The openFDA drug label record for set id 1a52bedc-8e2c-4116-a296-a87770676b4a (manufacturer Viatris Specialty LLC, application NDA021437), returned on 2026-11-18. The label text is dated 2025-06-23 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%221a52bedc-8e2c-4116-a296-a87770676b4a%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1.2 Hypertension. Retrieved 2026-11-18T17:27:10Z. Source state: Current. Version fingerprint: 5faf76d843730007ed843afc66f467edf02eeccc748524c7f0b7abcfb7138e90.
     How it applies: Label passage quoted in the research quote table (LB-07).
  4. Background: openFDA drug label record for Inspra (eplerenone tablets), Viatris Specialty LLC label: indications, mechanism, class (Regulator, edition The openFDA drug label record for set id 1a52bedc-8e2c-4116-a296-a87770676b4a (manufacturer Viatris Specialty LLC, application NDA021437), returned on 2026-11-18. The label text is dated 2025-06-23 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%221a52bedc-8e2c-4116-a296-a87770676b4a%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-18T17:27:10Z. Source state: Current. Version fingerprint: 5faf76d843730007ed843afc66f467edf02eeccc748524c7f0b7abcfb7138e90.
     How it applies: Effective date of the label text read, 20250623.

## Connected pages

- Eplerenone is an aldosterone antagonist (FDA established pharmacologic class in RxClass): Mineralocorticoid receptor antagonists (drug class) (`cardio:mineralocorticoid-receptor-antagonists`)
- FDA label lists improving survival in stable adults with symptomatic heart failure with reduced ejection fraction after an acute myocardial infarction as an indication: Heart failure with reduced ejection fraction (HFrEF) (`cardio:hfref`) [a claim, not a settled fact; see claim `cardio:claim-fda-eplerenone-label-indications` and its context]
- FDA label lists heart failure after an acute myocardial infarction as the setting of its first indication: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`) [a claim, not a settled fact; see claim `cardio:claim-fda-eplerenone-label-indications` and its context]
- FDA label lists the treatment of hypertension in adults as an indication: Hypertension (high blood pressure) (`core:hypertension`) [a claim, not a settled fact; see claim `cardio:claim-fda-eplerenone-label-indications` and its context]
- The mineralocorticoid receptor antagonist class is one of the four classes of the heart failure regimen: Four-class medicine regimen in heart failure (guideline-directed medical therapy) (`cardio:hfref-four-medicine-regimen`)
- Files under this front: Medicines (`cardio:front-medicines`)

## Provenance

Content hash: 4612b467615436888490472bfc6632488a260a40e454e5ad3a1a476556a66950
Last substantive edit: 2026-11-18
Evidence last checked: 2026-11-18
